BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample - PowerPoint PPT Presentation

Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ Investor Presentation Richard T. Schumacher November 2019 President, CEO, and Founder

FORWARD LOOKING STATEMENTS This presentation may contain forward looking statements that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company’s filings with the Securities and Exchange Commission. 02

COMPANY OVERVIEW (OTCQB: PBIO) Three Business Segments - Three Unique Technology Platforms ➢ Research Products and Services ( PCT Platform ) • PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules) • Focus: to streamline and improve the characterization and quality control of protein therapeutics for the Biopharma market. Also offers an effective means of rapid, consistent, and reliable sample preparation for biomarker and target discovery and clinical diagnostics and research laboratories. • 15 Patents, 325 PCT Systems installed, 200+ customers, 120+ publications, FY2018 revenue ($2.4M) ➢ Biopharma Contract Services ( BaroFold Platform ) • BaroFold: Pressure Enabled Disaggregation and Controlled Refolding of Proteins • Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for disaggregation & controlled refolding of recombinant proteins into their native structures for desired drug activity. • 8 Patents, Dec 2017 BaroFold Inc. Acquisition, Commercial Launch of BCS Business on Jan 7, 2019 ➢ Nanoemulsion Manufacturing Services ( UST Platform ) • UST: Ultra Shear Technology (uniquely combines high hydrostatic pressure & intense shear forces) • Focus: to produce higher quality, more stable nanoemulsions with improved absorption, higher bioavailability, and lower surfactant levels: results in better quality food, pharmaceuticals, nutraceuticals, cosmetics, and cannabis oil extracts (water soluble CBD) compared to standard emulsions • 2 Patents, Commercial Launch of BaroShear K45 in July 2019 3

COMPANY MANAGEMENT (OTCQB: PBIO) • Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’ l Mgr) - Harvard Medical School • Dr. Edmund Y. Ting, Senior VP of Engineering Avure Technologies (CTO); Flow Int’l (VP R&D); Grumman Aerospace; Pioneer in High Pressure Processing for “Clean Label”, Safe Food; MIT (Ph.D.) • Dr. Alexander V. Lazarev, Senior VP and CSO Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.) • Dr. Alexander V. Lazarev, Senior VP and CSO Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.) • Dr. Nathan Lawrence, Senior Advisor (recently retired VP of S&M at PBI) Becton Dickinson, Boston Biomedica, 454 Life Sciences, Pressure BioSciences, Inc. Board • Jeffrey Peterson, MS Board Chairman • Kevin Pollack, Esq., MBA Chairman: Audit Committee • Vito Mangiardi, MBA Chairman: Compensation Committee • Mickey Urdea, Ph.D. Chairman: SAB • Richard T. Schumacher CEO, Treasurer, Clerk 4

PCT Platform RESEARCH PRODUCTS & SERVICES 02

QUALITY OF ANALYSES IN RESEARCH STUDIES (DISCOVERY TO CLINIC) DEPENDS SIGNIFICANTLY ON THE QUALITY OF SAMPLE PREPARATION 6

THREE CRITICAL FUNCTIONS IN SCIENTIFIC RESEARCH STUDIES Sample Input Quality = Sample Result Quality Data Sample Analysis Reduction & Preparation Interpretation ✓ Quality of Analytical Equipment & Data Reduction has Increased Over Recent Years ✓ Quality of Methods for Sample Preparation have not Increased Proportionally (weak link) ✓ Quality of Results is Significantly Affected by the Quality of the Sample Preparation ✓ Scientific Discoveries Start with Sample Preparation 7

VALUE PROPOSITION: RESEARCH & BIOPHARMA INDUSTRY • Analysis of Proteins, Lipids, DNA, RNA, and Small Molecules (“biomolecules”) from Biological Samples is the Backbone of the Research & Biopharma Industry (Discovery to Clinic) • Quality of Results Depends Significantly on Quality of Sample Preparation • Current Sample Preparation Methods are Highly Inadequate: Bottleneck • PCT: Proven Sample Prep Platform with ~ 300 PCT Systems Installed in about 200 Different Sites Worldwide • 120+ Publications Highlight the Advantages of the PCT Platform in Research, Biopharma Sample Preparation (from Discovery to Characterization to QC to Clinic), Protein Therapeutics Characterization and QC • Biological Sample Preparation (Proteomics, Genomics, Lipidomics, Metabolomics) is a Multi-Billion Dollar Market Comprised of an Estimated 500,000 Scientists in 80,000 Research Labs Worldwide 8

MARKET OPPORTUNITIES: PCT PLATFORM GENOMICS NEXT GEN MASS SPECTROMETRY SAMPLE PREP (DNA/RNA) SEQUENCING (DNA) (PROTEINS) FOR ALL OMICS $5.27B by 2022 d $9.3B by 2025 e $27.6B by $16.35B by 2025 b 2024 c 500,000 SCIENTISTS ALL BIOPHARMA ALL PROTEOMICS IN 80,000 BIOLOGICAL $526B by 2025 g $72.44B by RESEARCH LABS WORLDWIDE a 2021 f a EMMES Group | b Research and Markets (August 2018) | c Markets and Markets (Aug 2018) | d Markets and Markets (Nov 2017) | e Coherent Market Insights (Jan 2019) | f Allied Market Research (March 2019) | g Allied Market Research (July 2018) 9

BAROCYCLER 2320EXTREME FOR BIOLOGICAL SAMPLE PREPARATION & QC (DISCOVERY TO CLINIC) SPECIFICATIONS cGxP-compliant Data Logging and Audit Trails - 16 samples per batch - Full support for MicroPestle platform - Pressure: up to 45,000 psi (3.1 kilobar) - Temperature: 4 ° C to 95 ° C (external chiller) or Ambient to 95 ° C (built-in electrical heater) - Unlimited pressure programming - Real-time graphs of pressure and temperature - Enhanced security and user management - Safe low voltage (24V DC) operation 10

PBI INSTRUMENT PORTFOLIO BAROCYCLER™ HUB440 - HUB880 BAROZYME HT48 XSTREAMPCT™ 2320EXT Up to 45,000 psi. Award- Up to 58,000 & Up to 20,000 psi. Up to 58,000 winning, next-generation, 100,000 psi. High throughput psi. On-line multi-functional sample All-purpose pressure analyses sample preparation instrument generators processors 4 1 2 3 5 6 7 Up to 25,000 psi. Lab-Scale UST Novel Pressure Homogenizers Pump EXPLORER ULTRA-SHEAR RF 1700 11 DISCOVERY PLATFORM TECHNOLOGY (UST)

APPLICATIONS OF PBI PRODUCTS & SERVICES SPAN ACROSS ALL BIOPHARMA MARKET SEGMENTS FROM DISCOVERY TO CLINIC DEVELOPMENT DISCOVERY CLINIC 12

PCT PLATFORM IN THE LABS OF KOLS WORLDWIDE Professor J. Van Eyk Prof. Patricia Okubara Professor Cathy Royer Professor Wayne Hubbell Ced edars Sinai USD SDA – WSU SU Re Renssel elaer Po Poly. y. Inst. UCLA Biomarker Discovery Biomarker Discovery Protein Folding Kinetics Protein Structure Heart Disease Microbe Diversity in Soil Rational Drug Design Drug Discovery & Design Professor Bruce Kristal Professor Bruce McCord Prof. Ruedi Aebersold Prof. Phil Robinson Harv Ha rvard Me Medical School Florida Int’l Univ. ET ETH, Zuri rich, Swi Switzer erland Pr ProCan (CMRI), Syd ydney, y, AU AU Metabolomics/Lipidomics Forensics – DNA Testing WW Proteomic Leader Proteomic Mass Spec for Fecal Lipidomic Profiling Improved Rape Kit Testing Tissue Biopsy Analysis by PCT-SWATH Precision Medicine & Therapy 13

BAROFOLD PLATFORM BIOPHARMA CONTRACT SERVICES & Licensing 02

VALUE PROPOSITION: BAROFOLD PLATFORM Patented Process for Disaggregation and Controlled Refolding of Proteins • Most New Drugs are Biological not Chemical • Over 200 Protein Drugs on Market – Many Additional Protein Drugs in Development • Proteins Can Aggregate and Misfold in Manufacturing: Critical Issue • Pressure (BaroFold Platform) Can Disaggregate and Refold Proteins: Addresses Critical Issue • Improves Quality of Protein Drugs and Reduces Cost of Manufacturing • Potential for Millions of Dollars in Annual Revenue from Biotherapeutic Company Licenses • BaroFold Technology Works Well on PBI Instruments (R&D) • Expect Increase in PBI Instrument Sales from Companies Developing Protein-based Drugs 15

MARKET OPPORTUNITIES: GLOBAL BIOPROCESSING OF PROTEIN-BASED DRUGS The BaroFold Platform helps companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. The BaroFold Platform is scalable and practical for standard manufacturing processes. According to a Report from Transparency Market Research (July 2018), the Global Bioprocess Technology Market will reach an estimated $44B by 2026. ___________________ • Disease Indications Monoclonal Antibodies – Rheumatoid Arthritis • Interleukins – Psoriasis/Psoriatic Arthritis • Vaccines – Cancer • Growth Factors – Diabetes 16